Rob Dillard

DocwireNews

Using an oral hypomethylating agent (HMA) may alleviate some treatment challenges in myelodysplastic syndromes (MDS), according to a study published in Clinical Lymphoma, Myeloma &amp; Leukemia. &ldquo;Until recently, patients with MDS could receive HMAs via intravenous (IV) or subcutaneous (SC) administration. An oral HMA was recently approved as an alternative to IV/SC administration. This study assessed the impact of IV/SC HMA on MDS patients, and their experience of, challenges with, and views about oral MDS treatment,&rdquo; the researchers wrote.Researchers conducted an online cross-sectional survey representing 141 patients with MDS (comprising 120 patients and 21 caregiver proxies) invited by two U.S. MDS patient advocacy groups. To meet the inclusion criteria, patients were required to have received IV/SC HMA within six months of taking the survey. Median patient age was 63.0 years, and 53.9% were women. The rates of low-risk, high-risk, and unknown risk MDS were 19.8%, 62.4%, and 17.7%, respectively.Following an injection, most SC HMA recipients reported pain (94.2%) and interference with daily (86.5%) and social (80.8%) activities. The majority of patients (69.5%) indicated they would prefer oral MDS treatment to IV/SC therapies.&ldquo;Patients receiving IV/SC HMAs experienced pain/discomfort and interference with social and daily activities,&rdquo; the researchers concluded. &ldquo;The introduction of an oral HMA may alleviate some treatment challenges for MDS patients.&rdquo;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Injectable Hypomethylating Agents for Managing MDS

Using an oral hypomethylating agent (HMA) may alleviate some treatment challenges in myelodysplastic syndromes (MDS), according to a study published in Clinical Lymphoma, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe